177 related articles for article (PubMed ID: 11596086)
21. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
Hempel G; Galle PR; Löhr HF
J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
[TBL] [Abstract][Full Text] [Related]
22. Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA;
J Gastroenterol Hepatol; 2013 Nov; 28(11):1770-81. PubMed ID: 23663030
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients.
Rodríguez-Torres M; Burguera J; Hallman D; Rodríguez-Orengo J; Echeandia M
Ann Hepatol; 2012; 11(4):450-63. PubMed ID: 22700626
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
25. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
Zekri AR; Haleem HA; Esmat GE; Bahnassy AA; El-Din HM; Hafez MM; Sharaby AF; Sharaf H; Zakaria MS
J Viral Hepat; 2007 Jul; 14(7):468-77. PubMed ID: 17576388
[TBL] [Abstract][Full Text] [Related]
27. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1.
Stegmann KA; Björkström NK; Ciesek S; Lunemann S; Jaroszewicz J; Wiegand J; Malinski P; Dustin LB; Rice CM; Manns MP; Pietschmann T; Cornberg M; Ljunggren HG; Wedemeyer H
J Infect Dis; 2012 May; 205(9):1351-62. PubMed ID: 22457290
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells.
Schlaak JF; Pitz T; Löhr HF; Meyer zum Büschenfelde KH; Gerken G
J Med Virol; 1998 Oct; 56(2):112-7. PubMed ID: 9746065
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
Talal AH; Ribeiro RM; Powers KA; Grace M; Cullen C; Hussain M; Markatou M; Perelson AS
Hepatology; 2006 May; 43(5):943-53. PubMed ID: 16761329
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
[TBL] [Abstract][Full Text] [Related]
31. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C.
Piazzolla G; Tortorella C; Fiore G; Fanelli M; Pisconti A; Antonaci S
J Interferon Cytokine Res; 2001 Jul; 21(7):453-61. PubMed ID: 11506737
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy.
Zhang ZX; Milich DR; Peterson DL; Birkett A; Schvarcz R; Weiland O; Sällberg M
J Infect Dis; 1997 Jun; 175(6):1294-301. PubMed ID: 9180166
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
36. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Osinusi A; Rasimas JJ; Bishop R; Proschan M; McLaughlin M; Murphy A; Cortez KJ; Polis MA; Masur H; Rosenstein D; Kottilil S
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):357-63. PubMed ID: 20101190
[TBL] [Abstract][Full Text] [Related]
37. Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment.
Bozkaya H; Bozdayi AM; Aslan N; Türkay C; Sarioglu M; Cetinkaya H; Akdogan M; Cinar K; Erden E; Köse K; Sentürk H; Akkiz H; Karayalcin S; Yurdaydin C; Uzunalimoglu O
Infection; 2000 Sep; 28(5):309-13. PubMed ID: 11073139
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection.
Barrett S; Collins M; Kenny C; Ryan E; Keane CO; Crowe J
J Med Virol; 2003 Oct; 71(2):212-8. PubMed ID: 12938195
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
[TBL] [Abstract][Full Text] [Related]
40. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
Jacobson IM; Brown RS; McCone J; Black M; Albert C; Dragutsky MS; Siddiqui FA; Hargrave T; Kwo PY; Lambiase L; Galler GW; Araya V; Freilich B; Harvey J; Griffel LH; Brass CA;
Hepatology; 2007 Oct; 46(4):982-90. PubMed ID: 17894323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
